China’s Simcere Zaiming signs $1.5 B deal with Roche for SIM0660 global development
September 2, 2026 | Wednesday | News
SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology
image credit- shutterstock
Simcere Zaiming, a subsidiary of China-based Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for the development and commercialisation of SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.
Under the terms of the agreement, Roche will acquire exclusive global rights to develop, manufacture, and commercialise SIM0660.
Simcere Zaiming is eligible to receive up to $1.5 billion in total payments, including $75 million in upfront. Simcere Zaiming is also eligible to receive tiered royalties of up to double digits on future net sales.
SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release.
With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell mediated diseases, and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit.
To date, Simcere Pharmaceutical Group has completed six out-licensing transactions, with a potential aggregate total consideration exceeding $6.1 billion.